Diabetes Drug Invokana® or Related Drugs Linked to Diabetic Ketoacidosis by FDA
Invokana, a prescription drug used to control blood sugar in patients with Type 2 diabetes, has been linked to serious complications including ketoacidosis and kidney failure. In May 2015, the Food and Drug Administration (FDA) issued a warning which stated that the sodium-glucose co-transporter-2 (SGLT2) inhibitor medication, used to treat diabetes, may be linked to an increased risk of diabetic ketoacidosis (DKA). According to research by the FDA, SGLT2 drugs such as Invokana, Invokamet, Farxiga, Xigduo XR, Jardiance, or Glyxambi, have been used by patients who have been diagnosed with DKA. Potentially fatal complications can be detected by the following symptoms: difficulty breathing, nausea, vomiting, abdominal pain, and unusual fatigue.
If you or a loved one has suffered from diabetic ketoacidosis and are taking SGLT2 inhibitors such as Invokana, please call today to schedule your FREE consultation with Tucson Attorney Sarah J. Showard to discuss your case: (520) 622-3344 or toll free (866) 307-2147.
Showard Law Firm
4703 E. Camp Lowell Drive, Suite 253
Tucson, AZ 85712
Sarah J. Showard, Attorney At Law
Se Habla Español
Trademark Notice: The use of the name of any product is strictly for identification purposes in attorney advertising. Showard Law Firm is in no way affiliated with the manufacturer of any product referenced on this site